Spironolactone
Product Images NDC 68071-2977

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 68071-2977). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2977 9)

Pdp (68071 2977 9)
SPIRONOLACTONE 100mg tablets label from NuCare Pharmaceuticals, Inc. The label indicates a bottle containing 90 oval, white, scored tablets debossed with 'MP 303'. It includes the NDC (68071-2977-9), product number P2126090, and storage instructions to keep at controlled temperature 68-77°F, with a warning to keep out of reach of children.*
FDA Label Image

Structure (Spironolactonens 01)

Structure (Spironolactonens 01)
Chemical structure of spironolactone shown as a detailed molecular diagram with labeled functional groups.*
FDA Label Image

Figure1 (Spironolactonens 02)

Figure1 (Spironolactonens 02)
A Kaplan-Meier survival curve comparing the probability of an event over time in months for Spironolactone (solid line) and placebo (dashed line) groups. The graph shows decreasing probabilities over 48 months, with Spironolactone and placebo groups indicated by sample sizes of 822 and 841, respectively. A log-rank p-value of less than 0.001 is noted.*
FDA Label Image

Figure 2 (Spironolactonens 03)

Figure 2 (Spironolactonens 03)
A forest plot showing hazard ratios (HR) with 95% confidence intervals (CI) for various subgroups in a study comparing spironolactone to placebo. Subgroups include age, sex, race, LVEF percentage, heart failure type, NYHA class, diabetes, serum creatinine, creatinine clearance, potassium levels, digoxin use, ACE inhibitor use, and beta blocker use. The plot visually compares the effectiveness of spironolactone versus placebo across these categories.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.